Cho N, Fukunaga K, Kunii K, Kobayashi I
Department of Obstetrics and Gynecology, Showa University, Fujigaoka Hospital.
Jpn J Antibiot. 1991 Jun;44(6):674-82.
Pharmacokinetic, bacteriological and clinical studies on flomoxef (FMOX) in the perinatal period were carried out with the following summary of the results. Antibacterial effects of FMOX on the growth of methicillin-resistant Staphylococcus aureus (MRSA, MIC 400 micrograms/ml), methicillin-sensitive S. aureus (MSSA, MIC 0.78 microgram/ml), Escherichia coli (MIC 3.13 micrograms/ml and MIC 0.20 microgram/ml) in amniotic fluid were determined and it was found that the activity of FMOX was enhanced in the amniotic fluid. FMOX rapidly penetrated into tissues and sera of pregnant women upon intravenous injection and its maternal serum concentrations reached their peak levels shortly after administration. Placental penetration of FMOX to the fetus was good and, after single intravenous injection of 1 g, the concentrations of FMOX in the umbilical cord serum and amniotic fluid exceeded MICs against major causative organisms of perinatal infections. These results indicate that single intravenous injection of FMOX 1 g twice a day is effective for the treatment and prophylaxis of perinatal infections. Injection of FMOX for the treatment of 14 cases of puerperal infections showed excellent clinical effectiveness with 100% clinical effect and 81.8% bacteriological response. No side-effect was observed in any case. All of these results suggested clinical usefulness of FMOX in the perinatal period.
对氟氧头孢（FMOX）在围产期进行了药代动力学、细菌学及临床研究，结果总结如下。测定了FMOX对羊水内耐甲氧西林金黄色葡萄球菌（MRSA，MIC为400微克/毫升）、甲氧西林敏感金黄色葡萄球菌（MSSA，MIC为0.78微克/毫升）、大肠杆菌（MIC为3.13微克/毫升和MIC为0.20微克/毫升）生长的抗菌作用，发现FMOX在羊水中的活性增强。静脉注射后，FMOX迅速渗透到孕妇的组织和血清中，给药后不久母体血清浓度达到峰值。FMOX对胎儿的胎盘渗透良好，单次静脉注射1克后，脐带血清和羊水中FMOX的浓度超过了对围产期感染主要病原体的MIC。这些结果表明，每天两次单次静脉注射1克FMOX对围产期感染的治疗和预防有效。注射FMOX治疗14例产褥期感染显示出极佳的临床疗效，临床有效率为100%，细菌学反应率为81.8%。未观察到任何副作用。所有这些结果表明FMOX在围产期具有临床应用价值。
